Case Report

Pulmonary Mucormycosis: A Case Report of a Rare Infection with Potential Diagnostic Problems

Salwa O. Mekki,1,2 Amal A. Hassan,1,3 Afnan Falemban,1 Nashwa Alkotani,4 Salem M. Alsharif,5 Ahmed Haron,6 Basim Felemban,6 Mohammad S. Iqbal7, and Aisha Tabassum7

1Pathology Department, Alnoor Specialist Hospital, Makkah, Saudi Arabia
2Faculty of Medicine, Al Neelain University, Khartoum, Sudan
3Faculty of Medicine, Al-Azhar University, Cairo, Egypt
4Department of Medicine, Alnoor Specialist Hospital, Makkah, Saudi Arabia
5Medical Department, Alnoor Specialist Hospital, Makkah, Saudi Arabia
6Radiology Department, Alnoor Specialist Hospital, Makkah, Saudi Arabia
7Department of Pathology, Faculty of Applied Medical Sciences, Umm Al Qura University, Makkah, Saudi Arabia

Correspondence should be addressed to Mohammad S. Iqbal; mmiqbal@uqu.edu.sa

Received 10 November 2019; Accepted 30 December 2019; Published 9 January 2020

Academic Editor: Piero Tosi

Copyright © 2020 Salwa O. Mekki et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Pulmonary mucormycosis is a relatively rare pulmonary fungal disease, which is difficult to diagnose early and lacks effective treatment. It is seen in patients with hematological malignancies, diabetes mellitus, and immunocompromised states. The diagnosis depends primarily on the detection of fungi in lung tissue. Here, we present a case of a 52-year-old male who has type 2 diabetes mellitus and a past history of treated pulmonary tuberculosis. Clinical diagnosis is difficult in pulmonary mucormycosis, and early diagnosis is needed for this life-threatening infection. Histopathological examination of a resected cavity confirmed the diagnosis of pulmonary mucormycosis. This report highlights the difficulty of diagnosis and the importance of histological examination in detecting mucormycosis which will help for early management.

1. Introduction

Mucormycosis is a rare opportunistic fungal infection. It derives its name from the Mucorales order of filamentous fungi and family Mucoraceae. It is a less common opportunistic fungal infection compared to Candida and Aspergillus species [1]. There are six most commonly reported forms which include rhinocerebral, pulmonary, cutaneous, gastrointestinal, disseminated, and uncommon presentations [2, 3]. The relative incidence of pulmonary mucormycosis (PM) to other clinical form incidence in literature is about 25% [4]. Diabetes mellitus, systemic corticosteroid therapy, neutropenia, hematologic malignancies, stem cell transplant, and immunocompromised state are the predisposing situations for mucormycosis [3, 4]. Pulmonary mucormycosis results from the inhalation of sporangiospores or by hematogenous or lymphatic spread [3, 5]. Patients present with nonspecific symptoms like cough, dyspnea, chest pain, and fever [3, 5]. Clinical diagnosis is difficult in pulmonary mucormycosis, and early diagnosis is needed for this life-threatening infection. Histopathological examination of a resected cavity confirmed the diagnosis of pulmonary mucormycosis. This report highlights the difficulty of diagnosis and the importance of histological examination in detecting mucormycosis which will help for early management.
2. Case Report

A 52-year-old male patient, known diabetic, presented to the emergency department with a complaint of hemoptysis. There was no fever, chest pain, or bleeding from other sites. No history of weight loss or night sweats. The patient is an old treated pulmonary tuberculosis case. There is no history of any drug intake. On admission, the patient was stable. General physical examination was insignificant. Local examination revealed upper lobe crepitation. CT chest angiography and chest radiograph (Figures 1 and 2) revealed right upper lobe partial collapse and old healed pulmonary tuberculosis of the right upper lobe with underlying cavitation and bronchiectasis. A well-defined, hypodense, nonenhancing lesion is noted in the cavitation that was reported as a mucous plug or a fungus ball. Right bronchial arteries were hypertrophied and tortuous. There was no endobronchial lesion or mucosal abnormalities. The right bronchial tree showed minimal hemorrhage. There was a cavity in the right apex. There were no aneurysms or vascular malformations. No significant changes were associated with bronchiectatic changes. Bronchoalveolar lavage analysis showed inflammatory cells, macrophages, and degenerated cells. There was no evidence of malignancy. Culture was done for bronchoalveolar lavage, and no growth was identified. Direct microscopic examination was not done.

CT angiography and right bronchial artery shunt embolization was performed. After embolization, the patient was stable, and no more complaints of hemoptysis were reported. The patient was discharged and put on voriconazole 200 mg per oral q12h and levofloxacin 500 mg per oral q24h. Four days after discharge, the patient came to the emergency department with complaint of hemoptysis. On examination, the patient was vitally stable. Right upper lobe crepitations were present. General physical examination was unremarkable. Laboratory investigations showed a hemoglobin of 10 gm/dl, total WBC count of 19,300 cells/cumm, and platelets 4.02 lakhs/cumm. Biochemical investigations revealed a BUN of 5.71 mmol/l and creatinine 75 μmol/l. The thoracic surgery unit was consulted, and they took the patient for surgical management. Thoracotomy and limited resection of the lung lesion including the fungal ball from the right upper lobe was done, and the sample was sent for pathological examination. Microscopic examination of lesion revealed lung tissue filled with colonies of broad, nonseptate right-angled branching fungal hyphae. Gomori’s methenamine silver stain highlighted the fungi with spores. There were many epithelioid cells admixed with mixed inflammatory infiltrates. A diagnosis of pulmonary mucormycosis was done on histopathology (Figures 3–6). Postsurgery culture was negative. After confirmation, voriconazole was changed to liposomal amphotericin B 5 mg/kg IV q24h for total 6 weeks. The patient could not be followed up later.

3. Discussion

Mucormycosis encompasses a group of infections caused by the fungi belonging to the order Mucorales and family Mucoraceae [1, 7]. Rhizopus oryzae is the most common
Mucormycosis is an opportunistic life-threatening infection mostly occurring in the immunocompromised host. The risk of infection from the Mucoraceae family is followed by Mucor sp. and Lichtheimia sp. Inhalation of ubiquitous spores is the main mode of infection. There is no evidence of human to human transmission [8]. Recent reclassification has abolished the class zygomycetes, and hence, the term zygomycosis is inappropriate for use, although it may still be used to address mucormycosis [1]. Pulmonary mucormycosis is a devastating and life-threatening infection if not correctly diagnosed and treated [9]. The mononuclear and polymophonuclear phagocytes of normal hosts kill Mucorales by generation of oxidative metabolites and the cationic defensins. Defensive mechanisms in normal hosts are mediated by macrophages that inhibit germination of spores and neutrophils that kill hyphal elements by oxidative burst. Macrophage dysfunction is the cause for infection in diabetes patients [10]. Weak host defenses are a major risk factor for pulmonary mucormycosis. Neutropenic patients as well as patients with elevated serum iron levels are also at increased risk of developing mucormycosis [5].

Pulmonary mucormycosis may develop as a result of inhalation of spores or by hematogenous or lymphatic spread. Portal of entry for Mucorales is the respiratory tract where the fungi can easily invade arteries, veins, and lymphatics and produce thrombosis and infarction which can be fatal [11–13].

Invasive pulmonary mucormycosis causes severe morbidity and mortality in patients with hematological malignancies, diabetes mellitus, hematopoietic stem cell transplant and solid organ transplant patients, patients on corticosteroid-based therapy, iron overload and chelation therapy, intravenous drug use, trauma, burns, neonatal prematurity, and malnutrition [14–19]. The sequelae include angioinvasion and direct tissue injury of the respiratory tract, direct extension from the lungs into the great vessels, invasion from the paranasal sinuses into the orbit and brain, and hematogenous dissemination to the central nervous system [14, 20]. Clinical presentations may include nonspecific symptoms like fever, dyspnea, cough, and chest pain, and rarely, they can present as progressive subcutaneous emphysema, Pancoast syndrome, Horner’s syndrome, and bronchial perforation [21]. Angioinvasion results in necrosis of parenchymal tissue, cavitation and/or hemoptysis which may be fatal if a major blood vessel is involved [22].

In a large review of 929 cases of zygomycosis, an overall mortality of 44% was reported in diabetics with zygomycosis and 76% mortality for pulmonary zygomycosis in patients with other predisposing factors. Rhizopus species were the most common organism in patients of zygomycosis in whom hematological malignancies were the predisposing factor [16].

Histopathology and direct microscopy along with culture for various clinical specimens are the major diagnostic modalities for mucormycosis. Sputum and BAL cytology are unpredictable and may be negative [10, 23]. Histopathologically, mucormycosis species appear as broad, nonseptate hyphae with right angle branching and can be differentiated from Aspergillus which shows regular, septate, and acute angle branching hyphae [24].

Radiological findings described in literature are the presence of nodule or consolidation, isolated mass, cavitation, or lung abscess with fungal ball. Wedge-shaped infarcts of the lung may also be seen, particularly following thrombosis of the pulmonary vessels due to fungal angioinvasion. High-resolution CT scan is the best method of determining the extent of pulmonary mucormycosis and may demonstrate evidence of infection. Expansion of a mass or consolidation across tissue planes towards the great vessels in the mediastinum may suggest the diagnosis [25, 26]. “Reverse halo sign” is described as a prominent CT finding present in the early course of disease [5].

Differential diagnosis of PM involves bacterial, viral, and other fungal pneumonias and invasive fungal infections can be a diagnostic challenge [27]. Invasive PM needs to be distinguished from invasive aspergillosis as the two respond differently to antifungal agents [24]. Confirmation by microscopic examination is necessary as treatment will differ. In our case, before confirmation by histopathology, the patient was put on voriconazole, and after confirmation, it was changed to liposomal amphotericin B. Rarely, PM may recur even in an immunocompetent host [28]. Lipid formulation of amphotericin B is the first-line therapy for mucormycosis [29].

4. Conclusion

Mucormycosis is an opportunistic life-threatening infection mostly occurring in the immunocompromised host. The risk
conflict of interest. Diagnosis is difficult due to non-specific presentation. Early diagnosis and treatment which includes surgery and antifungal drugs can improve outcome and survival. Definitive diagnosis required pathologic demonstration of the organism in affected tissue as sputum and BAL culture rarely shows growth. The best promising diagnostic modalities should be applied at the earliest to avoid unnecessary treatment with voriconazole and promoting early specific management of mucormycosis.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

References

[1] B. Spellberg and J. Maertens, "Mucormycosis," in Principles and Practice of Transplant Infectious Diseases, A. Saifdar, Ed., Springer, New York, NY, 2019.
[2] E. Pennell, I. Pecson, C. Nakamura, and A. E. Galvis, "Pulmonary mucormycosis in an adolescent female with type 1 diabetes mellitus," IDCases, vol. 14, p. e00474, 2018.
[3] A. Serris, F. Danion, and F. Lanternier, "Disease entities in mucormycosis," Journal of Fungi, vol. 5, no. 1, p. 23, 2019.
[4] Z. Luo and L. Zhang, "Diagnosis and treatment of pulmonary mucormycosis: a case report," Experimental and Therapeutic Medicine, vol. 14, no. 4, pp. 3788–3791, 2017.
[5] B. Spellberg, J. Edwards, and A. Ibrahim, "Novel perspectives on mucormycosis: pathophysiology, presentation, and management," Clinical Microbiology Reviews, vol. 18, no. 3, pp. 556–569, 2005.
[6] B. Nam, T. J. Kim, K. S. Lee, T. S. Kim, J. Han, and M. J. Chung, European Radiology, vol. 28, no. 2, pp. 788–795, 2018.
[7] A. Mohammadi, A. Meh dizadeh, M. Ghasemi-Rad, H. Habilpourn, and A. Esmaei, "Pulmonary mucormycosis in patients with diabetic ketoacidosis: a case report and review of literature," Tuberk Toraks, vol. 60, no. 1, pp. 66–69, 2012.
[8] S. Point, F. Gabriel, H. Bégueret et al., "Tumor shape pulmonary mucormycosis associated with sinonasal aspergillosis in a diabetic patient," Medical microbiology case reports, vol. 19, pp. 13–17, 2018.
[9] N. Iqbal, M. Irfan, K. Jabeen, M. M. Kazmi, and M. U. Tariq, "Chronic pulmonary mucormycosis: an emerging fungal infection in diabetes mellitus," Journal of Thoracic Disease, vol. 9, no. 2, pp. E121–E125, 2017.
[10] J. Guarner and E. Brandt, "Histopathologic Diagnosis of fungal infections in the 21st Century," Clinical Microbiology Reviews, vol. 24, no. 2, pp. 247–280, 2011.
[11] J. P. Green and D. J. Karras, "Commentary," Annals of Emergency Medicine, vol. 59, no. 1, pp. 54–55, 2012.
[12] H. S. Yamin, A. Y. Alastal, and I. Bakri, "Pulmonary mucormycosis over 130 years: a case report and literature review," Turkish Thoracic Journal, vol. 18, no. 1, pp. 1–5, 2017.
[13] G. Henglass, J. A. Elliott, and N. P. Lucie, "An unusual presentation of opportunistic mucormycosis," British Medical Journal (Clinical Research Ed.), vol. 282, no. 6258, pp. 108–109, 1981.
[14] T. J. Walsh, M. N. GAMEsou, M. R. McGinnis, R. T. Hayden, and D. P. Kontoyiannis, "Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis)," Clinical Infectious Diseases, vol. 54, suppl_1, pp. S55–S60, 2012.
[15] G. M. Cox, "Mucormycosis (zygomycosis)," 2019, Literature review current through: UpToDate. Last updated.
[16] M. M. Roden, T. E. Zaoutis, W. L. Buchanan et al., "Epidemiology and outcome of Zygomyces: a review of 929 reported cases," Clinical Infectious Diseases, vol. 41, no. 5, pp. 634–653, 2005.
[17] H. C. Pillsbury and N. D. Fischer, "Rhinocerebral mucormycosis," Archives of Otolaryngology, vol. 103, no. 10, pp. 600–604, 1977.
[18] J. W. Tomford, D. Whittlesey, J. E. Ellner, and J. F. Tomashefski Jr., "Invasive primary cutaneous phycomycosis in diabetic leg ulcers," Archives of Surgery, vol. 115, no. 6, pp. 770–771, 1980.
[19] M. Tedder, J. A. Spratt, M. P. Anstadt, S. S. Hegde, S. D. Tedder, and J. E. Lowe, "Pulmonary mucormycosis: results of medical and surgical therapy," The Annals of Thoracic Surgery, vol. 57, no. 4, pp. 1044–1050, 1994.
[20] P. Khatiwada, A. Giri, and P. Khatiwoda, "Mucormycosis in diabetes mellitus," Journal of Advances in Internal Medicine, vol. 1, no. 2, pp. 73–75, 2012.
[21] X.-M. Wang, L.-C. Guo, S.-L. Xue, and Y.-B. Chen, "Pulmonary mucormycosis: a case report and review of the literature," Oncology Letters, vol. 11, no. 5, pp. 3049–3053, 2016.
[22] R. Garg, R. S. K. Marak, S. K. Verma, J. Singh, Sanjay, and R. Prasad, "Pulmonary mucormycosis mimicking as pulmonary tuberculosis: a case report," Lung India, vol. 25, no. 3, pp. 129–131, 2008.
[23] S. Challa, S. G. Uppin, M. S. Uppin, R. T. Paul, A. K. Prayaga, and M. T. Rao, "Pulmonary zygomycosis: a clinicopathological study," Lung India, vol. 28, no. 1, pp. 25–29, 2011.
[24] J. G. Song, S. H. Kang, B. W. Jung, H. S. Oh, M. J. Kim, and S. H. Lee, "Invasive pulmonary aspergillosis histologically mimicking mucormycosis," The Ewha Medical Journal, vol. 39, no. 2, pp. 65–68, 2016.
[25] M. C. Fitzpatrick and B. W. Carter, "Pulmonary mucormycosis complicating cutaneous blastic plasmacytid dendritic cell neoplasms," Baylor University Medical Center Proceedings, vol. 25, no. 3, pp. 287–288, 2012.
[26] H. P. McAdams, M. Rosado de Christenson, D. C. Strollo, and E. F. Patz Jr., "Pulmonary mucormycosis: radiologic findings in 32 cases," American Journal of Roentgenology, vol. 168, no. 6, pp. 1541–1548, 1997.
[27] H. Tanriverdi, F. Atalay, L. Kart, M. Altuntas, and A. Tomruk, "A case of pulmonary mucormycosis presenting with endobronchial involvement," Eurasian Journal of Pulmonology, vol. 16, no. 3, pp. 189–191, 2015.
[28] L. Zhang, X. Tian, P. Wang, H. Zhang, and R. Feng, "Recurrent pulmonary mucormycosis after lobectomy in a non-smoking patient without predisposing risk factors," The Brazilian Journal of Infectious Diseases, vol. 16, no. 6, pp. 590–593, 2012.
[29] A. Skaida, C. Lass-Floerl, N. Klimko, A. Ibrahim, E. Roilides, and G. Petrikkos, "Challenges in the diagnosis and treatment of mucormycosis," Medical Mycology, vol. 56, suppl_1, pp. S93–S101, 2018.